Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Hikmat Abdel-Razeq


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


H. Abdel-Razeq, S.S. Saadeh, R. Malhis, O. AL-Natour, S. Yaser, H. Abdulelah, R. Eljaber, G. Khalaf

Author affiliations

  • Internal Medicine, King Hussein Cancer Center KHCC, 11195 - Amman/JO


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 712


Anemia in cancer patients undergoing chemotherapy is commonly encountered and may worsen their quality of life. Because of recent concerns about their negative effect on overall survival and serious adverse events, erythropoiesis-stimulating agents (ESA) are not commonly prescribed. This study will assess the efficacy and safety of intravenous ferric carboxymaltose (FCM) therapy in such patients.


Adult patients with non-myeloid malignancies on chemotherapy with Hemoglobin (Hb)≤ 11.0 g/dL and a life expectancy >24 weeks were recruited. Based on serum ferritin (sFr) level and transferrin saturation (TSAT), patients were categorized into three Groups: Group-I (Absolute Iron Deficiency: AIDA) with sFr <30 ng/mL and TSAT <20%. Group-II (Functional Iron Deficiency Anemia: FIDA) with sFr 30-800 ng/mL and TSAT <20%. Patients with TSAT >20% were placed in group-III as “others”. Based on Hb level and body weight, patients were given FCM in one or two short intravenous infusions.


A total of 84 patients; 70 (83.3%) females were recruited. Median age [standard deviation] was 53.8 [10.6] years. Chemotherapy varied according to the primary cancer and many had it as a second-line or beyond. The median Hb level at baseline was 10.2 (range: 8.3-11.0 ) gm/dL. At week-12, patients with AIDA (26,31.0%) and FIDA (24, 28.6%) had a significant increment in Hb (median increment: 2.35 and 1.5 gm/dL, respectively). Patients in Group-III (34, 40.5%) had limited response. Most of the increment (≥1.0 g/dL) occurred as early as week-3. No immediate infusion-related adverse events were reported. However, asymptomatic hypophosphatemia was observed in 39 (46.4%) patients (table).Table:


VariablesAbsolute iron deficiency (n = 26)Functional iron deficiency (n = 24)Others (n = 34)P-value
Ferritin Level (week 12, mg/mL) Mean (SD) Median (range)589 (509) 442 (177-2794)838 (875) 577 (168-4184)956 (667) 802 (166-2687)0.0247
Phophorus level (week 2, mg/dL) Mean (SD) Median (range)1.8 (0.7) 1.5 (1.1-3.4)2.5 (1.0) 3.3 (1.0-5.4)2.2 (0.9) 3.3 (1.0-4.1)0.0124
Hypophophatemia Number Percentage17 65.4%6 25.0%16 47.1%


Intravenous FCM, without ESA, is safe and effective in the treatment of anemia in cancer patients undergoing active treatment with chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


King Hussein Cancer Center.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.